A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma
This is a randomized, double-blind, placebo-controlled, crossover study comparing asthma control post treatment in African American/Black and Caucasian/White children in both hyper and hypo responsive HILD (Histamine Lontophoresis with Laser Doppler monitoring) phenotypes with uncontrolled persistent allergic asthma using Levocetirizine (LTZ) vs placebo.
• A diagnosis of asthma based on physician diagnosis
• A diagnosis of uncontrolled asthma based on Asthma Control Test (ACT) score within the last 3 months or at screening
• Evidence of allergic sensitization based on allergy skin test or allergy blood test results
• Individuals who are currently being treated with asthma guideline-based therapy
• Males and females 6 through 17 years of age at time of enrollment
• Willing to provide written permission/assent to participate
• Children who self-identify as African American/black (identify both 1st degree (parents) and 2nd degree relatives (grandparents) as African American) or Caucasian/white (self-report of 1st and 2nd degree relatives as Caucasian)